LR-India, also known as Lloyd's Register India, is a part of the Lloyd's Register group, which is a global professional services organization specializing in engineering, technology, and business services. The company provides compliance, assurance, and performance services to help clients ensure the quality, safety, and reliability of their operations in various sectors.

Lightrock provides patient capital and business-building support to world-class entrepreneurs across three key themes - Unlocking human potential, equitably; Building resource efficiency, sustainably; Reimagining business productivity, responsibly - covering key sectors such as Food and Agriculture, Logistics, Mobility, Healthcare, Renewable energy, Education and Financial services.

Our thematic platform approach to investing stems from our belief that every firm operates not in isolation but through a set of symbiotic relationships with players across the value chain in their sector. The ability to think through these interconnections and find ways to improve system-level outcomes across firms can create a virtuous cycle of value creation that significantly outpaces mere individual firm growth.

Lightrock invests between $10 and $50M in a company. We also have the ability to invest significantly higher amounts in situations that offer a compelling fit to our investment thesis and mission.

Lightrock India team will continue to manage investments for the SONG Fund and Aspada Investment company

www.aspada.com

Lightrock India

The team at Bugworks Research Inc. has been pursuing its mission to develop a novel broad-spectrum antibiotic compound, BWC0977 to treat serious infections caused by multidrug-resistant bacteria. We congratulate the Bugworks team and welcome this investment, development and commercialization support from the world's leading organization dedicated to furthering research to combat anti-microbial resistance. Apart from accelerating the clinical development of BWC0977, Global Antibiotic R&D Partnership (GARDP) will also enable manufacturing and commercialization in a total of 148 countries, including nearly all low- and middle-income countries, allowing unprecedented global reach for BWC0977, impacting patients across the world. 

https://lnkd.in/di5gZM6W

Gender disparities in access to quality healthcare is a pressing problem and we are incredibly proud of the BeatO team for reaching this milestone where they have recorded a 20x growth in the number of female users over the last 5 years, cumulatively reaching over 600K lives as on date. Keeping in line with the company’s focus to democratize the access to specialist diabetes care well beyond the metro cities, 60% of this female patient base is from outside Tier 1 geographies. Notably, around ~45% of this patient population is sub 45 years of age, indicating the company’s ability to drive awareness and adoption among a younger patient population with a strong value proposition that is helping people identify and treat their diabetes early.

https://lnkd.in/ghBqPqca

COM:LR-INDIA

LR-India

Analysis Not Available